Trials / Unknown
UnknownNCT05368207
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient (Pemb-HT)
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Detailed description
It is an open-label single patient Clinical Trial to be conducted at Princess Margaret Cancer Centre for a patient with Small Cell Carcinoma of Ovary - Hypercalcemic Type (SCCOHT) who has rare and aggressive malignancy with no current consensus on treatment approach and surveillance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1. |
Timeline
- Start date
- 2021-12-06
- Primary completion
- 2024-11-02
- Completion
- 2024-11-02
- First posted
- 2022-05-10
- Last updated
- 2024-03-13
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT05368207. Inclusion in this directory is not an endorsement.